In 2020 the world will need an extra 34 million gallons of diesel fuel per day. That's 12 billion gallons per year.
The pre-commercial gold miner has announced a string of positive updates in November.
Inject a little above-average wealth-building potential into your portfolio with any -- or all -- of these three stocks.
The stock was downgraded by a top Wall Street firm. Will it really matter in a few months, or even weeks?
Three short years ago, Myriad Genetics was the undisputed leader of the genetic testing industry. A persistent competitor just challenged the diagnostic company -- and a second one is nipping at its heels.
The company published SEC filings that go into more detail than its recent press release -- and investors don't like what they see.
The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.
Covia Holdings announced third-quarter 2018 results that made Mr. Market think things aren't so bad after all for this corner of the oil and gas industry.
Codexis is on pace to become the first publicly-traded synthetic biology company to deliver consistent operating profits. Investors should take note.
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
The troubled precious metal miner is being acquired by Pan American Silver, but investors are sending the acquirer's shares down more than double digits on the news.
The synthetic biology pioneer reported third-quarter 2018 operating results.
Income investors can sleep soundly at night owning any of these solid businesses in their retirement accounts.
Renewable energy from wind and solar went from impossibly expensive to nearly 10% of American electricity in less than 20 years. What's ahead may be even more astounding.
The U.S.-China trade fight has weighed on shares of these two solid businesses in 2018. That creates an opportunity for long-term investors.
Investors sent shares soaring yesterday, but the future is still chock full of uncertainty for the generic drug distributor.
After earning FDA marketing approval for a controversial new drug, the company is raising cash through a share offering.
The struggling drug developer reported third-quarter 2018 operating results and raised $210 million in debt.
Stock market slides are rarely kind to development-stage biopharma companies. Did October's sell-off create any opportunities for investors?
A handful of updates heading into a critical regulatory review date had investors reconsidering a healthy market cap.